@article {Reynolds2022.02.25.22271515, author = {Shannon L. Reynolds and Harvey W. Kaufman and William A. Meyer III and Chris Bush and Oren Cohen and Kathy Cronin and Carly Kabelac and Sandy Leonard and Steve Anderson and Valentina Petkov and Douglas Lowy and Norman Sharpless and Lynne Penberthy}, title = {Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World Data}, elocation-id = {2022.02.25.22271515}, year = {2022}, doi = {10.1101/2022.02.25.22271515}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Importance Better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection is needed.Objective Primary: To assess the durability of immunity to SARS-CoV-2 reinfection among initially unvaccinated individuals with previous SARS-CoV-2 infection. Secondary: Evaluate the crude SARS-CoV-2 reinfection rate and associated characteristics.Design and Setting Retrospective observational study of HealthVerity data among 144,678,382 individuals, during the pandemic era through April 2021.Participants Individuals studied had SARS-CoV-2 molecular diagnostic or antibody index test results from February 29 through December 9, 2020, with >=365 days of pre-index continuous closed medical enrollment, claims, or electronic health record activity.Main Outcome(s) and Measure(s) Rates of reinfection among index-positive individuals were compared to rates of infection among index-negative individuals. Factors associated with reinfection were evaluated using multivariable logistic regression. For both objectives, the outcome was a subsequent positive molecular diagnostic test result.Results Among 22,786,982 individuals with index SARS-CoV-2 laboratory test data (2,023,341 index positive), the crude rate of reinfection during follow-up was significantly lower (9.89/1,000-person years) than that of primary infection (78.39/1,000 person years). Consistent with prior findings, the risk of reinfection among index-positive individuals was 87\% lower than the risk of infection among index-negative individuals (hazard ratio, 0.13; 95\% CI, 0.13, 0.13). The cumulative incidence of reinfection among index-positive individuals and infection among index-negative individuals was 0.85\% (95\% CI: 0.82\%, 0.88\%) and 6.2\% (95\% CI: 6.1\%, 6.3\%), respectively, over follow-up of 375 days. The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval. Factors associated with an increased reinfection risk included older age, comorbid immunologic conditions, and living in congregate care settings; healthcare workers had a decreased reinfection risk.Conclusions and Relevance This large US population-based study demonstrates that SARS-CoV-2 reinfection is uncommon among individuals with laboratory evidence of a previous infection. Protection from SARS-CoV-2 reinfection is stable up to one year. Reinfection risk was primarily associated with age 85+ years, comorbid immunologic conditions and living in congregate care settings; healthcare workers demonstrated a decreased reinfection risk. These findings suggest that infection induced immunity is durable for variants circulating prior to Delta.Question How long does prior SARS-CoV-2 infection provide protection against SARS-CoV-2 reinfection?Finding Among \>22 million individuals tested February 2020 through April 2021, the relative risk of reinfection among those with prior infection was 87\% lower than the risk of infection among individuals without prior infection. This protection was durable for up to a year. Factors associated with increased likelihood of reinfection included older age (85+ years), comorbid immunologic conditions, and living in congregate care settings; healthcare workers had lower risk.Meaning Prior SARS-CoV-2 infection provides a durable, high relative degree of protection against reinfection.Competing Interest StatementAll authors completed the ICMJE uniform disclosure form at: www.icmje.org/coi_disclosure.pdf and declare: Shannon L. Reynolds and Christopher Bush had full access to all the data and take full responsibility for the integrity of the data and the accuracy of the data analysis. Shannon L. Reynolds, Carly Kabelac, and Christopher Bush are employees of and own stock in Aetion, Inc. Harvey W. Kaufman and William A. Meyer III are employees of and own stock in Quest Diagnostics. Oren Cohon and Steve Anderson are employees of and own stock in Labcorp Drug Development. Steve Anderson has received consulting fees from Luminex. Douglas Lowry has received royalty-related payments from NIH. Kathy Cronin, Sandy Leonard, Valentina Petkov, Norman Sharpless, and Lynne Penberthy report no conflict of interests.Funding StatementAetion, Inc., employer of Shannon L. Reynolds, Chris Bush and Carly Kabelac, was contracted and sponsored by NCI to conduct this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New England Institutional Review Board ($\#$1-9757-1) waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2022/02/26/2022.02.25.22271515}, eprint = {https://www.medrxiv.org/content/early/2022/02/26/2022.02.25.22271515.full.pdf}, journal = {medRxiv} }